Sara Shalin
Concepts (437)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 36 | 2025 | 496 | 9.690 |
Why?
| | Skin Diseases | 7 | 2022 | 118 | 3.770 |
Why?
| | Melanoma | 16 | 2024 | 272 | 3.750 |
Why?
| | Dermatology | 9 | 2024 | 54 | 3.120 |
Why?
| | Skin | 12 | 2024 | 416 | 2.980 |
Why?
| | Carcinoma, Basal Cell | 6 | 2025 | 40 | 2.550 |
Why?
| | Immunohistochemistry | 19 | 2025 | 977 | 2.030 |
Why?
| | Biopsy | 21 | 2025 | 594 | 1.920 |
Why?
| | Nevus, Pigmented | 3 | 2024 | 34 | 1.820 |
Why?
| | Sebaceous Gland Neoplasms | 5 | 2022 | 16 | 1.700 |
Why?
| | Staining and Labeling | 3 | 2021 | 92 | 1.520 |
Why?
| | Adenocarcinoma, Sebaceous | 3 | 2022 | 7 | 1.470 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2025 | 44 | 1.460 |
Why?
| | Humans | 88 | 2025 | 52441 | 1.390 |
Why?
| | Carcinoma, Merkel Cell | 3 | 2025 | 41 | 1.370 |
Why?
| | Nevus, Blue | 2 | 2021 | 11 | 1.290 |
Why?
| | Melanocytes | 3 | 2021 | 38 | 1.280 |
Why?
| | Female | 49 | 2025 | 28277 | 1.220 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 75 | 1.200 |
Why?
| | Dermatitis | 2 | 2022 | 36 | 1.180 |
Why?
| | Erythema Multiforme | 2 | 2020 | 11 | 1.110 |
Why?
| | Middle Aged | 33 | 2025 | 13133 | 1.100 |
Why?
| | Diagnosis, Differential | 15 | 2025 | 1028 | 1.090 |
Why?
| | Aged | 29 | 2025 | 10242 | 1.060 |
Why?
| | Aged, 80 and over | 18 | 2024 | 3449 | 0.990 |
Why?
| | Vasculitis | 2 | 2024 | 28 | 0.990 |
Why?
| | Vulvar Neoplasms | 3 | 2022 | 60 | 0.990 |
Why?
| | Alopecia | 2 | 2024 | 38 | 0.950 |
Why?
| | Herpes Simplex | 2 | 2022 | 25 | 0.930 |
Why?
| | Urticaria | 1 | 2025 | 19 | 0.910 |
Why?
| | Sebaceous Glands | 2 | 2024 | 13 | 0.890 |
Why?
| | Adult | 25 | 2025 | 14205 | 0.890 |
Why?
| | Skin Diseases, Vascular | 1 | 2024 | 8 | 0.890 |
Why?
| | Neoplasm Staging | 2 | 2024 | 768 | 0.870 |
Why?
| | Incidental Findings | 1 | 2024 | 43 | 0.870 |
Why?
| | Dermatitis, Seborrheic | 1 | 2024 | 4 | 0.870 |
Why?
| | Sweat Gland Neoplasms | 3 | 2024 | 22 | 0.860 |
Why?
| | Atrophy | 1 | 2024 | 46 | 0.850 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2024 | 119 | 0.830 |
Why?
| | Plasma Cells | 1 | 2025 | 233 | 0.820 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 15 | 0.820 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 170 | 0.810 |
Why?
| | Fibroma | 3 | 2025 | 40 | 0.810 |
Why?
| | Male | 34 | 2025 | 26874 | 0.790 |
Why?
| | Hyperoxaluria | 1 | 2022 | 3 | 0.790 |
Why?
| | Urolithiasis | 1 | 2022 | 4 | 0.790 |
Why?
| | Hyperoxaluria, Primary | 1 | 2022 | 3 | 0.790 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 91 | 0.770 |
Why?
| | Adenoma | 2 | 2017 | 114 | 0.770 |
Why?
| | Pathology | 2 | 2020 | 37 | 0.770 |
Why?
| | Epidermal Cyst | 1 | 2022 | 12 | 0.760 |
Why?
| | Granuloma | 2 | 2020 | 45 | 0.750 |
Why?
| | Carcinoma in Situ | 1 | 2022 | 72 | 0.740 |
Why?
| | Protein Kinases | 2 | 2016 | 73 | 0.730 |
Why?
| | Muscle, Smooth | 1 | 2021 | 63 | 0.720 |
Why?
| | Fungi | 1 | 2021 | 51 | 0.700 |
Why?
| | Elastic Tissue | 2 | 2020 | 10 | 0.700 |
Why?
| | Artifacts | 1 | 2021 | 53 | 0.690 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.690 |
Why?
| | Foreign Bodies | 1 | 2021 | 66 | 0.690 |
Why?
| | Scabies | 2 | 2025 | 6 | 0.680 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2020 | 2 | 0.680 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 2020 | 14 | 0.680 |
Why?
| | Methenamine | 1 | 2020 | 1 | 0.670 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2020 | 2 | 0.670 |
Why?
| | Lichenoid Eruptions | 1 | 2020 | 3 | 0.670 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 205 | 0.670 |
Why?
| | Vulvar Diseases | 1 | 2020 | 7 | 0.670 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 61 | 0.670 |
Why?
| | Lymphatic Metastasis | 2 | 2020 | 210 | 0.660 |
Why?
| | Genitalia | 1 | 2020 | 10 | 0.660 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2020 | 51 | 0.660 |
Why?
| | Lichen Sclerosus et Atrophicus | 1 | 2020 | 7 | 0.660 |
Why?
| | Syphilis | 1 | 2020 | 20 | 0.660 |
Why?
| | Gynecology | 1 | 2020 | 52 | 0.650 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 65 | 0.640 |
Why?
| | Young Adult | 11 | 2025 | 4346 | 0.630 |
Why?
| | Pseudoxanthoma Elasticum | 1 | 2019 | 4 | 0.620 |
Why?
| | Pathology, Surgical | 1 | 2019 | 23 | 0.600 |
Why?
| | Pathology, Clinical | 4 | 2021 | 25 | 0.590 |
Why?
| | Telangiectasis | 1 | 2018 | 3 | 0.570 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.570 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2024 | 331 | 0.560 |
Why?
| | Carcinoma, Large Cell | 1 | 2017 | 17 | 0.550 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2017 | 27 | 0.550 |
Why?
| | Laryngeal Neoplasms | 1 | 2017 | 43 | 0.540 |
Why?
| | Hidrocystoma | 1 | 2017 | 5 | 0.540 |
Why?
| | Calcium Oxalate | 1 | 2017 | 7 | 0.540 |
Why?
| | Apocrine Glands | 1 | 2017 | 7 | 0.540 |
Why?
| | Inflammation | 2 | 2020 | 649 | 0.520 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 224 | 0.490 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 58 | 0.480 |
Why?
| | Transcription Factors | 2 | 2021 | 570 | 0.480 |
Why?
| | Brain Neoplasms | 2 | 2020 | 302 | 0.470 |
Why?
| | Sarcoptes scabiei | 1 | 2015 | 2 | 0.460 |
Why?
| | Genital Diseases, Male | 1 | 2015 | 17 | 0.450 |
Why?
| | Lymphangioma | 1 | 2014 | 8 | 0.450 |
Why?
| | Histiocytosis, Sinus | 1 | 2015 | 14 | 0.450 |
Why?
| | Scrotum | 1 | 2015 | 31 | 0.450 |
Why?
| | Arm | 1 | 2014 | 46 | 0.420 |
Why?
| | Adolescent | 9 | 2025 | 6713 | 0.420 |
Why?
| | Acanthoma | 1 | 2013 | 2 | 0.420 |
Why?
| | Fibroadenoma | 1 | 2013 | 7 | 0.420 |
Why?
| | Eccrine Glands | 1 | 2013 | 11 | 0.420 |
Why?
| | Nuclear Proteins | 1 | 2014 | 247 | 0.400 |
Why?
| | Leuprolide | 1 | 2012 | 3 | 0.390 |
Why?
| | Mucinosis, Follicular | 1 | 2012 | 3 | 0.390 |
Why?
| | Drug Eruptions | 1 | 2012 | 14 | 0.380 |
Why?
| | Endometriosis | 1 | 2012 | 15 | 0.380 |
Why?
| | Mycosis Fungoides | 1 | 2012 | 26 | 0.380 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2012 | 34 | 0.380 |
Why?
| | Cicatrix | 1 | 2012 | 42 | 0.380 |
Why?
| | Thrombosis | 1 | 2015 | 250 | 0.370 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 56 | 0.370 |
Why?
| | Dermis | 2 | 2021 | 19 | 0.350 |
Why?
| | Social Media | 3 | 2018 | 120 | 0.350 |
Why?
| | Histones | 3 | 2020 | 315 | 0.350 |
Why?
| | Cesarean Section | 1 | 2012 | 182 | 0.340 |
Why?
| | Vulva | 2 | 2020 | 18 | 0.340 |
Why?
| | Mucous Membrane | 2 | 2020 | 33 | 0.330 |
Why?
| | Muir-Torre Syndrome | 1 | 2010 | 1 | 0.320 |
Why?
| | Neutrophils | 2 | 2025 | 148 | 0.320 |
Why?
| | Hippocampus | 3 | 2006 | 231 | 0.310 |
Why?
| | Gene Rearrangement | 2 | 2021 | 76 | 0.310 |
Why?
| | Mutation | 4 | 2024 | 1331 | 0.280 |
Why?
| | Epithelioid Cells | 2 | 2020 | 12 | 0.280 |
Why?
| | Up-Regulation | 3 | 2020 | 462 | 0.280 |
Why?
| | Retrospective Studies | 5 | 2025 | 6694 | 0.270 |
Why?
| | Dermatomycoses | 2 | 2016 | 16 | 0.260 |
Why?
| | Factor XIIIa | 2 | 2016 | 10 | 0.250 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2016 | 202 | 0.250 |
Why?
| | Mutation, Missense | 3 | 2020 | 108 | 0.250 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 57 | 0.240 |
Why?
| | Memory | 1 | 2006 | 107 | 0.240 |
Why?
| | Antifungal Agents | 3 | 2016 | 347 | 0.240 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 128 | 0.240 |
Why?
| | Memory Disorders | 1 | 2006 | 52 | 0.240 |
Why?
| | Postoperative Complications | 1 | 2012 | 1065 | 0.230 |
Why?
| | Signal Transduction | 2 | 2016 | 1724 | 0.230 |
Why?
| | Mast Cells | 1 | 2025 | 55 | 0.220 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2024 | 3 | 0.220 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2024 | 25 | 0.220 |
Why?
| | Neurons | 2 | 2006 | 442 | 0.220 |
Why?
| | SOXE Transcription Factors | 2 | 2021 | 4 | 0.210 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2019 | 600 | 0.210 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 48 | 0.210 |
Why?
| | MART-1 Antigen | 2 | 2021 | 12 | 0.210 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 871 | 0.210 |
Why?
| | Chickenpox | 1 | 2024 | 17 | 0.210 |
Why?
| | Nevus | 1 | 2024 | 16 | 0.210 |
Why?
| | Lymphoma | 1 | 2024 | 71 | 0.210 |
Why?
| | Carcinoma | 1 | 2024 | 135 | 0.200 |
Why?
| | Disease Outbreaks | 1 | 2024 | 121 | 0.200 |
Why?
| | Fear | 1 | 2004 | 84 | 0.200 |
Why?
| | Oxalates | 1 | 2022 | 10 | 0.200 |
Why?
| | Angioedema | 1 | 2022 | 11 | 0.190 |
Why?
| | Kidney Transplantation | 1 | 2025 | 199 | 0.190 |
Why?
| | Demography | 1 | 2022 | 92 | 0.190 |
Why?
| | Sarcoidosis | 1 | 2022 | 43 | 0.190 |
Why?
| | Foot | 1 | 2022 | 40 | 0.190 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2022 | 8 | 0.180 |
Why?
| | Prednisone | 1 | 2022 | 100 | 0.180 |
Why?
| | Plant Structures | 1 | 2021 | 5 | 0.180 |
Why?
| | Cotton Fiber | 1 | 2021 | 4 | 0.180 |
Why?
| | Herpesvirus 2, Human | 1 | 2021 | 4 | 0.180 |
Why?
| | Lymphokines | 1 | 2021 | 20 | 0.180 |
Why?
| | Paper | 1 | 2021 | 16 | 0.180 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 14 | 0.180 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2021 | 25 | 0.180 |
Why?
| | Histocytochemistry | 1 | 2021 | 44 | 0.180 |
Why?
| | Dermatofibrosarcoma | 1 | 2021 | 9 | 0.180 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 32 | 0.180 |
Why?
| | Sutures | 1 | 2021 | 36 | 0.180 |
Why?
| | Hyperplasia | 1 | 2021 | 96 | 0.180 |
Why?
| | Coloring Agents | 1 | 2021 | 68 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 2 | 2020 | 152 | 0.180 |
Why?
| | Animals | 10 | 2021 | 13485 | 0.180 |
Why?
| | Stromal Cells | 1 | 2021 | 76 | 0.180 |
Why?
| | Cadherins | 2 | 2019 | 61 | 0.180 |
Why?
| | Chromones | 1 | 2021 | 16 | 0.170 |
Why?
| | Lost to Follow-Up | 1 | 2020 | 10 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 853 | 0.170 |
Why?
| | Oncogene Fusion | 1 | 2020 | 4 | 0.170 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2021 | 21 | 0.170 |
Why?
| | Leprosy, Multibacillary | 1 | 2020 | 4 | 0.170 |
Why?
| | Armadillos | 1 | 2020 | 5 | 0.170 |
Why?
| | Research Report | 1 | 2020 | 19 | 0.170 |
Why?
| | Morpholines | 1 | 2021 | 64 | 0.170 |
Why?
| | Skin Transplantation | 1 | 2021 | 43 | 0.170 |
Why?
| | S100 Proteins | 2 | 2021 | 33 | 0.170 |
Why?
| | Histiocytes | 1 | 2020 | 10 | 0.170 |
Why?
| | Neoplasms, Fibrous Tissue | 1 | 2020 | 2 | 0.160 |
Why?
| | Papillomaviridae | 1 | 2020 | 102 | 0.160 |
Why?
| | Germ Cells | 1 | 2020 | 14 | 0.160 |
Why?
| | Graft Survival | 1 | 2021 | 157 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 86 | 0.160 |
Why?
| | Phagocytosis | 1 | 2020 | 54 | 0.160 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2020 | 8 | 0.160 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2020 | 59 | 0.160 |
Why?
| | Immunotherapy | 2 | 2019 | 251 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 71 | 0.160 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2020 | 88 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2021 | 132 | 0.160 |
Why?
| | Graft Rejection | 1 | 2021 | 166 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2024 | 403 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 75 | 0.160 |
Why?
| | Consensus | 1 | 2020 | 195 | 0.160 |
Why?
| | Elastin | 1 | 2019 | 23 | 0.150 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 9 | 0.150 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2019 | 31 | 0.150 |
Why?
| | Disease Progression | 3 | 2020 | 870 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 32 | 0.150 |
Why?
| | Melanoma, Experimental | 1 | 2019 | 34 | 0.150 |
Why?
| | Child | 4 | 2022 | 7194 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.140 |
Why?
| | Arteriovenous Malformations | 1 | 2019 | 74 | 0.140 |
Why?
| | Collagen | 1 | 2019 | 215 | 0.140 |
Why?
| | Acute Disease | 1 | 2019 | 384 | 0.140 |
Why?
| | Antigens, CD | 1 | 2019 | 213 | 0.140 |
Why?
| | Cricoid Cartilage | 1 | 2017 | 10 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 33 | 0.140 |
Why?
| | Dilatation | 1 | 2017 | 27 | 0.140 |
Why?
| | Tumor Burden | 1 | 2017 | 132 | 0.130 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2018 | 81 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 498 | 0.130 |
Why?
| | Connective Tissue Diseases | 1 | 2017 | 18 | 0.130 |
Why?
| | Parvoviridae Infections | 1 | 2017 | 19 | 0.130 |
Why?
| | Parvovirus B19, Human | 1 | 2017 | 16 | 0.130 |
Why?
| | Immunologic Surveillance | 1 | 2017 | 10 | 0.130 |
Why?
| | Tumor Escape | 1 | 2017 | 18 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2017 | 32 | 0.130 |
Why?
| | Histone Code | 1 | 2017 | 32 | 0.130 |
Why?
| | Rhizopus | 1 | 2016 | 4 | 0.130 |
Why?
| | Trachea | 1 | 2017 | 55 | 0.130 |
Why?
| | Sarcoma | 1 | 2018 | 68 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 46 | 0.130 |
Why?
| | RNA, Fungal | 1 | 2016 | 18 | 0.130 |
Why?
| | Mucormycosis | 1 | 2016 | 28 | 0.130 |
Why?
| | Connexins | 1 | 2016 | 25 | 0.130 |
Why?
| | Splenomegaly | 1 | 2016 | 12 | 0.130 |
Why?
| | Ascomycota | 1 | 2016 | 8 | 0.130 |
Why?
| | Angiomyoma | 1 | 2016 | 5 | 0.130 |
Why?
| | Mice | 6 | 2021 | 5899 | 0.130 |
Why?
| | Apoptosis | 3 | 2019 | 1120 | 0.120 |
Why?
| | Infant | 2 | 2015 | 3709 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2016 | 44 | 0.120 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2016 | 78 | 0.120 |
Why?
| | Recurrence | 2 | 2015 | 680 | 0.120 |
Why?
| | Human Growth Hormone | 1 | 2016 | 49 | 0.120 |
Why?
| | Candidiasis | 1 | 2016 | 112 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2016 | 132 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 187 | 0.120 |
Why?
| | Adipocytes | 1 | 2016 | 127 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 76 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2019 | 643 | 0.120 |
Why?
| | Avoidance Learning | 2 | 2006 | 17 | 0.120 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2015 | 16 | 0.120 |
Why?
| | Fibrin | 1 | 2015 | 10 | 0.120 |
Why?
| | Lysine | 1 | 2015 | 90 | 0.110 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2015 | 18 | 0.110 |
Why?
| | Facial Neoplasms | 1 | 2015 | 22 | 0.110 |
Why?
| | WT1 Proteins | 1 | 2014 | 4 | 0.110 |
Why?
| | Pigmentation Disorders | 1 | 2014 | 6 | 0.110 |
Why?
| | Carcinosarcoma | 1 | 2015 | 18 | 0.110 |
Why?
| | Immunocompromised Host | 3 | 2025 | 124 | 0.110 |
Why?
| | Purpura | 1 | 2014 | 7 | 0.110 |
Why?
| | Eosinophils | 1 | 2015 | 39 | 0.110 |
Why?
| | Keratin-20 | 1 | 2014 | 7 | 0.110 |
Why?
| | Hemangiosarcoma | 1 | 2014 | 18 | 0.110 |
Why?
| | United States | 2 | 2022 | 5215 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 125 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2018 | 317 | 0.110 |
Why?
| | Herpes Zoster | 1 | 2014 | 17 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2016 | 123 | 0.110 |
Why?
| | Loss of Heterozygosity | 1 | 2015 | 78 | 0.110 |
Why?
| | Prospective Studies | 1 | 2020 | 2433 | 0.110 |
Why?
| | Churg-Strauss Syndrome | 1 | 2014 | 3 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 336 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 116 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 127 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2015 | 294 | 0.110 |
Why?
| | Lymphocytes | 1 | 2015 | 146 | 0.110 |
Why?
| | Antigens, CD34 | 1 | 2014 | 73 | 0.110 |
Why?
| | Exanthema | 1 | 2014 | 33 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 328 | 0.110 |
Why?
| | Eosinophilia | 1 | 2014 | 32 | 0.110 |
Why?
| | Sarcoma, Kaposi | 1 | 2014 | 76 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 239 | 0.100 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 295 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 475 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2020 | 485 | 0.100 |
Why?
| | Head and Neck Neoplasms | 1 | 2016 | 289 | 0.100 |
Why?
| | Prognosis | 4 | 2019 | 2100 | 0.100 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2013 | 137 | 0.090 |
Why?
| | DNA Mismatch Repair | 1 | 2012 | 18 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2014 | 667 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 5508 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 938 | 0.090 |
Why?
| | Multiple Myeloma | 2 | 2016 | 3013 | 0.090 |
Why?
| | Asthma | 1 | 2014 | 313 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 580 | 0.080 |
Why?
| | Fatal Outcome | 2 | 2022 | 193 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 140 | 0.070 |
Why?
| | Phorbol Esters | 1 | 2006 | 4 | 0.060 |
Why?
| | Theta Rhythm | 1 | 2006 | 8 | 0.060 |
Why?
| | Association Learning | 1 | 2006 | 11 | 0.060 |
Why?
| | Amphotericin B | 2 | 2016 | 104 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 72 | 0.060 |
Why?
| | Isoproterenol | 1 | 2006 | 56 | 0.060 |
Why?
| | Maze Learning | 1 | 2006 | 38 | 0.060 |
Why?
| | Child, Preschool | 1 | 2015 | 4046 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 39 | 0.060 |
Why?
| | Protein Kinase C | 1 | 2006 | 72 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 83 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 235 | 0.060 |
Why?
| | Fingers | 1 | 2025 | 34 | 0.060 |
Why?
| | Permethrin | 1 | 2025 | 5 | 0.060 |
Why?
| | Ivermectin | 1 | 2025 | 10 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2019 | 1013 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2017 | 318 | 0.060 |
Why?
| | Intellectual Disability | 1 | 2006 | 127 | 0.050 |
Why?
| | Time Factors | 2 | 2016 | 2987 | 0.050 |
Why?
| | Superior Cervical Ganglion | 1 | 2004 | 5 | 0.050 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 12 | 0.050 |
Why?
| | Disease Notification | 1 | 2024 | 9 | 0.050 |
Why?
| | Sensory Thresholds | 1 | 2004 | 17 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2004 | 41 | 0.050 |
Why?
| | Exploratory Behavior | 1 | 2004 | 24 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 47 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2004 | 47 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2004 | 85 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 67 | 0.050 |
Why?
| | Shock | 1 | 2004 | 33 | 0.050 |
Why?
| | Physician's Role | 1 | 2024 | 50 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 152 | 0.050 |
Why?
| | Brain | 2 | 2019 | 1337 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2004 | 127 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 355 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 248 | 0.050 |
Why?
| | Behavior, Animal | 1 | 2004 | 190 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 587 | 0.050 |
Why?
| | Motor Activity | 1 | 2004 | 227 | 0.050 |
Why?
| | Eyelids | 1 | 2022 | 27 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2004 | 566 | 0.050 |
Why?
| | Desmin | 1 | 2022 | 7 | 0.050 |
Why?
| | Edema | 1 | 2022 | 63 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2294 | 0.050 |
Why?
| | Gene Expression | 1 | 2004 | 618 | 0.040 |
Why?
| | gp100 Melanoma Antigen | 1 | 2021 | 8 | 0.040 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2021 | 3 | 0.040 |
Why?
| | DNA, Viral | 1 | 2021 | 134 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2020 | 6 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 262 | 0.040 |
Why?
| | Soil Microbiology | 1 | 2020 | 18 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1365 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2004 | 1134 | 0.040 |
Why?
| | Societies, Medical | 1 | 2021 | 200 | 0.040 |
Why?
| | Retinoblastoma Protein | 1 | 2020 | 17 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2004 | 1583 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 16 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 304 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 1558 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 271 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 130 | 0.040 |
Why?
| | Ulcer | 1 | 2020 | 24 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 65 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2021 | 173 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 62 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 62 | 0.040 |
Why?
| | Malpractice | 1 | 2019 | 16 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 288 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2021 | 396 | 0.040 |
Why?
| | Microcirculation | 1 | 2019 | 64 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 69 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 446 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2020 | 601 | 0.040 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 656 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 441 | 0.040 |
Why?
| | Rats | 1 | 2004 | 3228 | 0.030 |
Why?
| | Rare Diseases | 1 | 2018 | 47 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 357 | 0.030 |
Why?
| | Cadaver | 1 | 2017 | 88 | 0.030 |
Why?
| | Larynx | 1 | 2017 | 30 | 0.030 |
Why?
| | Pressure | 1 | 2017 | 100 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2018 | 120 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 36 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 525 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 29 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 257 | 0.030 |
Why?
| | Debridement | 1 | 2016 | 51 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 725 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 461 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 161 | 0.030 |
Why?
| | Toes | 1 | 2016 | 15 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 36 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 56 | 0.030 |
Why?
| | Family | 1 | 2018 | 170 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 65 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 63 | 0.030 |
Why?
| | Treatment Refusal | 1 | 2016 | 35 | 0.030 |
Why?
| | Abscess | 1 | 2016 | 36 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 122 | 0.030 |
Why?
| | Triazoles | 1 | 2016 | 115 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 182 | 0.030 |
Why?
| | Cell Movement | 1 | 2017 | 271 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2016 | 181 | 0.030 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 45 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1483 | 0.030 |
Why?
| | Epigenomics | 1 | 2016 | 75 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 458 | 0.030 |
Why?
| | Methylation | 1 | 2015 | 124 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1888 | 0.030 |
Why?
| | Proteome | 1 | 2017 | 175 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 126 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2015 | 37 | 0.030 |
Why?
| | Scalp | 1 | 2015 | 43 | 0.030 |
Why?
| | Arkansas | 1 | 2020 | 2013 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2016 | 479 | 0.030 |
Why?
| | Bone Marrow | 1 | 2016 | 354 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2014 | 52 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 179 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 463 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2014 | 90 | 0.030 |
Why?
| | Lipodystrophy | 1 | 2013 | 9 | 0.030 |
Why?
| | Heterozygote | 1 | 2013 | 89 | 0.030 |
Why?
| | Incidence | 1 | 2016 | 1096 | 0.020 |
Why?
| | Muscular Atrophy | 1 | 2013 | 73 | 0.020 |
Why?
| | Syndrome | 1 | 2013 | 247 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 639 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 396 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 1349 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 1429 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 1045 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1507 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 1140 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1216 | 0.020 |
Why?
|
|
Shalin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|